Drug Trial Radar · NCT03874832
A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Nov 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
Sep 11, 2018
Primary completion
Nov 7, 2018
Study completion Nov 7, 2018
Sponsor
- Lead sponsor
- Satsuma Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 14, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Single-center, single-dose, open-label, 2-part, 3-period crossover (in each part), pharmacokinetic and safety study.
Conditions
- Migraine With Aura
- Migraine Without Aura
- Migraine
Interventions
DihydroergotamineDrug
Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
Primary outcomes
What the sponsor says the trial is designed to measure.
- STS101 Dose Selection - Part 1Time frame: Pre-dose through 48 hours post-dose
- DHE Relative Bioavailability - Part 2Time frame: Pre-dose through 48 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quotient Sciences Miami Inc.
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.